Neonatal effects of maternal nadolol therapy

Am J Obstet Gynecol. 1985 Aug 15;152(8):1045-6. doi: 10.1016/0002-9378(85)90559-9.


Described is the case of an infant, exposed during gestation to the beta-blocker nadolol, who experienced cardiorespiratory depression, mild hypoglycemia, and growth retardation. The longer duration of action of nadolol and the fact that it is only 30% protein bound make it less desirable than propranolol for use as a beta-blocker during pregnancy.

MeSH terms

  • Female
  • Fetal Distress / chemically induced
  • Growth Disorders / chemically induced*
  • Humans
  • Hypertension / drug therapy*
  • Hypoglycemia / chemically induced*
  • Infant, Newborn
  • Male
  • Nadolol
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Prenatal Exposure Delayed Effects*
  • Propanolamines / adverse effects*


  • Propanolamines
  • Nadolol